Drugs / fallypride
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03648892 | Sep 2018 → Mar 2022 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00801827 | Jan 2007 → Mar 2011 | morbid obesity | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00846040 | Feb 2009 → Feb 2014 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fallypride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03648892 ↗ |
| Known as | f-18 fallypride | “Drug: f-18 fallypride” NCT00846040 ↗ |
| Modality | Small molecule | — CHEMBL392158 ↗ |